Intensive Care Medicine

, Volume 39, Issue 5, pp 811–822

Randomised trials of 6 % tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis

Systematic Review

DOI: 10.1007/s00134-013-2863-6

Cite this article as:
Patel, A., Waheed, U. & Brett, S.J. Intensive Care Med (2013) 39: 811. doi:10.1007/s00134-013-2863-6

Abstract

Purpose

To assess the impact of 6 % tetrastarch [hydroxyethyl starch (HES) 130/0.4 and 130/0.42] in severe sepsis patients. The primary outcome measure was 90-day mortality.

Methods

A structured literature search was undertaken to identify prospective randomised controlled trials (RCTs) in adult patients with severe sepsis receiving 6 % tetrastarch (of potato or waxy maize origin) as part of fluid resuscitation in comparison with other non-HES fluids after randomisation in the critical care setting. A systematic review and meta-analysis were performed.

Results

Six RCTs were included (n = 3,033): three from 2012 (n = 2,913) had low risk of bias. Median tetrastarch exposure was 37.4 ml/kg (range 30–43 ml/kg). Ninety-day mortality was associated with tetrastarch exposure [relative risk (RR) 1.13; 95 % confidence interval (CI) 1.02–1.25; p = 0.02] compared with crystalloid. The number needed to harm (NNH) was 28.8 (95 % CI 14.6–942.5). Publication bias and statistical heterogeneity (I2 = 0 %) were not present. Tetrastarch exposure was also associated with renal replacement therapy (p = 0.01; NNH 15.7) and allogeneic transfusion support (p = 0.001; NNH 9.9). No difference between groups was observed for 28-day mortality, for comparison with colloid as control, or for waxy maize-derived tetrastarch, but power was lacking. Overall mortality was associated with tetrastarch exposure (RR 1.13; 95 % CI 1.02–1.25; p = 0.02).

Conclusions

In our analysis, 6 % tetrastarch as part of initial fluid resuscitation for severe sepsis was associated with harm and, as alternatives exist, in our view should be avoided.

Keywords

6 % tetrastarch6 % hydroxyethyl starch (HES) 130/0.4 or 0.42Severe sepsisMortalityRenal

Supplementary material

134_2013_2863_MOESM1_ESM.pdf (566 kb)
Supplementary material 1 (PDF 567 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg and ESICM 2013

Authors and Affiliations

  1. 1.Centre for Perioperative Medicine and Critical Care ResearchImperial College Healthcare NHS TrustLondonUK
  2. 2.MRC Clinical Sciences Centre and Centre for HaematologyImperial College LondonLondonUK
  3. 3.General Intensive Care Unit, Centre for Perioperative Medicine and Critical Care ResearchImperial College Healthcare NHS TrustLondonUK